Effectiveness of Natural Treatments for Psoriasis A Periodical Article
##plugins.themes.bootstrap3.article.main##
摘要
Background: it is indicated that Biological Therapies has great effect in dealing with Psoriasis. Differences in response rates of biologics for the treatment of moderate-to-severe plaque psoriasis have been reported in many published articles.
Objective: this paper aims to declare the effectiveness of biological therapies for psoriasis. Methods: using the search engine PubMed to prepare comprehensive literature about the specified topic.
Main results: it is indicated that psoriasis is a chronic inflammatory skin disease condition that involves altered expression of a broad spectrum of proinflammatory cytokines which are associated with activation of T cells and proliferation of keratinocytes.
Conclusion: The introduction of targeted biologic therapies has greatly improved the treatment options for psoriasis although the pathogenesis of the autoimmune skin disease has not been fully elucidated. The potential for psoriasis disease is implicit because altered expressions of cutaneous and systemic cytokines are well demonstrated in psoriasis patients.
##plugins.themes.bootstrap3.article.details##
##submission.howToCite##
参考
H. Kim, Cameron E. West, Shawn G. Kwatra, Steven R. and Jenna L. O'Neill (2012). Comparative Efficacy of Biologies in Psoriasis A Review. Am J Ciln Deimatoi 2012; 18 (6): 35-34.
J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Dermatol 2019; 159: 513–526.
C, Kimball A, Papp K et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: Lancet 2018; 31: 665–674.
A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006: 54: 61–63.
A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008: 58: 106–115.
Jaggu KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006: 298: 7–15.
Yow-Ming C. Wang, and Hae-Young Ahn (2015). Biological Products for the Treatment of Psoriasis: Therapeutic Targets, Pharmacodynamics and Disease-Drug-Drug Interaction Implications. The AAPS Journal, Vol. 16, No. 5, june 2014 (# 2016) .
W, Downing C, Tyring S. Systematic review of interleukin-[5]132, interleukin-175, and interleukin-243 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18:556–669.